Life Length

Life Length was incorporated on September 28, 2010, by Stephen J. Matlin and María Blasco Marhuenda. The company emerged from the Spanish National Cancer Research Centre as a commercial spin-off intended to bring telomere-measurement research into laboratory services and potential clinical applications. Its founding technology was associated with Blasco’s work on high-throughput quantitative fluorescence in situ hybridization, or HT Q-FISH, a method for examining telomere length at the cellular and chromosomal level. The scientific basis of the business is the role of telomeres in chromosome protection and cellular replication. Telomeres typically become shorter as cells divide, and critically short or dysfunctional telomeres can contribute to cellular senescence or cell death. Telomere biology is also affected by cancer, inherited conditions, ageing, environmental exposures, and other factors. Life Length therefore developed services intended to measure telomere characteristics and telomerase activity for research, health assessment, and disease-related investigations. A major institutional milestone came in 2016, when Life Length obtained CLIA certification. CLIA is a U.S. regulatory framework for clinical laboratories, and the company described itself as Spain’s only laboratory with that certification. The business has also reported ISO 15189 accreditation and permits or recognitions connected with laboratories and sample collection in several U.S. states and in the Madrid health system. Its facilities have been associated with Madrid and Tres Cantos, where the company has operated offices and laboratories. In 2017, Life Length moved further into clinical biomarker research through ONCOCHECK. The programme consisted of clinical studies designed to evaluate telomere-associated variables as possible indicators in cancer diagnosis and prognosis. The supplied reference describes research involving more than 1,200 adults and 300 children with different cancers, including breast, prostate, lung, and leukemia-related disease. The programme also cites work with major Spanish hospitals and studies of advanced solid tumours and chronic lymphocytic leukemia. European Union Horizon 2020 provided €3.1 million in support for the project. The company’s research agenda broadened beyond oncology. It participated in or was associated with projects involving lung-cancer risk, childhood cancer, brain ageing, biological ageing in twins, and frailty. The lung-cancer work sought to develop an algorithm that could identify people at elevated risk using telomere measurements. Brain Age research addressed prenatal and environmental influences on brain ageing and age-related neurological disease. EuroBATS used genetic and biological approaches in a large identical-twin cohort, while Frailomic examined biomarkers that might identify older people at risk of frailty and disability. The company also reported childhood-cancer studies involving approximately 100 children with cancer and healthy comparison participants. In 2021, Life Length opened a clinic at Paseo del General Martínez Campos 46 in Madrid. This represented an expansion from laboratory and research activity toward a more direct clinical setting. In 2022, the Spanish Agency for Medicines and Health Products approved the company’s prostate-cancer diagnostic tool. The test was described as a minimally invasive blood test intended to help clinicians identify patients at higher risk of aggressive prostate cancer when combined with existing screening methods. The company also launched HEALTHTAV in 2022. Life Length’s work has appeared in a broader scientific ecosystem through publications by the company, its clients, and collaborating researchers. Topics represented in the supplied references include telomere measurement, induced pluripotent stem cells, cartilage models, skin ageing, oxidative stress, prenatal development, meditation, nutrition, and telomerase activation. These publications indicate the breadth of research contexts in which the company’s testing has been used, but they do not by themselves establish that every associated finding was developed or owned by Life Length. The available reference material does not identify current chief executives, ownership, parent-company relationships, revenue, market share, or a verified active corporate website. Life Length is therefore best characterized on the available evidence as an active Spanish biotechnology and clinical-laboratory brand centered on telomere diagnostics, telomerase analysis, and biomarker development.

• 2022

  Prostate-cancer diagnostic approved in Spain

  [1]Life Lengthen.wikipedia.org

  The company's prostate-cancer diagnostic tool received approval from the Spanish Agency for Medicines and Health Products.

• 2022

  HEALTHTAV launched

  [1]Life Lengthen.wikipedia.org

  Life Length launched HEALTHTAV as a new product in its portfolio.

• 2021

  Madrid clinic opens

  [1]Life Lengthen.wikipedia.org

  Life Length opened a clinic on Paseo del General Martínez Campos in Madrid.

• 2017

  ONCOCHECK receives Horizon 2020 funding

  [1]Life Lengthen.wikipedia.org

  The cancer-biomarker research programme received €3.1 million from the European Union's Horizon 2020 programme.

• 2016

  CLIA certification obtained

  [1]Life Lengthen.wikipedia.org

  Life Length obtained Clinical Laboratory Improvement Amendments certification for its laboratory operations.

• 2010

  Company founded

  [1]Life Lengthen.wikipedia.org

  Stephen J. Matlin and María Blasco Marhuenda established Life Length as a spin-off from the Spanish National Cancer Research Centre.

A specialized biotechnology and laboratory-services company focused on telomere biology, cellular-ageing assessment, oncology biomarker research, and translational diagnostics.

• Laboratory diagnostics and research services

  Telomere length testing

  Life Length’s core offering measures telomere characteristics in biological samples using methods derived from high-throughput quantitative fluorescence in situ hybridization. The results are intended for research, health assessment, and investigation of disease-related biology. Telomere measurements can be used to study cellular ageing, cancer, regenerative medicine, and other conditions, although their clinical interpretation depends on the indication and validation framework.

• Molecular biology testing

  Telomerase measurement

  The company provides or has provided testing related to telomerase, the enzyme that can maintain or extend telomeres in particular cell types. Telomerase analysis complements telomere-length measurement by addressing a related mechanism of chromosome-end maintenance. The supplied sources do not specify the full assay menu, instrumentation, pricing, or current availability.

• In-vitro diagnostic · 2022

  Prostate-cancer diagnostic

  This minimally invasive blood-based test was developed to help identify patients who may face a higher risk of aggressive prostate cancer. It is intended to complement, rather than simply replace, existing screening approaches and to support clinical decision-making. The reference material states that the product received Spanish regulatory approval in 2022 and could potentially reduce unnecessary biopsies, but does not provide detailed performance statistics.

• Health assessment product · 2022

  HEALTHTAV

  HEALTHTAV was added to Life Length’s portfolio in 2022. The supplied material identifies it as a new product but does not provide enough detail to describe its precise assay format, intended users, clinical claims, or commercial distribution. It is associated with the company’s broader health and telomere-assessment proposition.

• 2017ONCOCHECK

  Spain · European Union

  ONCOCHECK was a clinical research programme examining telomere-associated variables as potential biomarkers for cancer diagnosis and prognosis. The programme included adult and pediatric cancer cohorts and covered several cancer types, with support from Spanish hospitals and Horizon 2020 funding.

  Outcome. The programme supported the development of additional oncology applications, according to the supplied reference material.

  Source

• 2022

  Introduce prostate-cancer diagnostic and HEALTHTAVProduct launch

  Background

  Life Length sought to convert its telomere-biology platform into healthcare products and expanded its portfolio beyond laboratory research services.

  Action taken

  The company brought a prostate-cancer blood test to market after Spanish regulatory approval and launched HEALTHTAV.

  Aftermath

  The moves strengthened the company's stated focus on clinical diagnostics and health assessment, although detailed commercial results are unavailable.

  Source

• 2017

  Expand into oncology biomarker validationStrategy

  Background

  Life Length pursued clinical validation of telomere-associated variables in cancer through the ONCOCHECK programme.

  Action taken

  The company conducted studies involving adult and pediatric cancer populations and multiple disease areas, including prostate, breast, lung, and blood cancers.

  Aftermath

  The supplied material states that the research enabled new oncology applications, including development of a prostate-cancer diagnostic.

  Horizon 2020 project funding. €3.1 million (2017)

  Source

• 2010

  Commercialize HT Q-FISH-derived telomere researchStrategy

  Background

  The founders created Life Length as a research spin-off with the objective of translating telomere-measurement science from the Spanish National Cancer Research Centre into commercial laboratory and diagnostic applications.

  Action taken

  The company focused its business on telomere testing, telomerase analysis, and related biomarker research services.

  Aftermath

  This strategy formed the basis for later laboratory accreditation, clinical studies, and oncology product development.

  Source

1. 1Life Lengthen.wikipedia.org